agreement
commerci
assay
strongmidrang
ct
discord
identifi
low
posit
sampl
ct
review
endpoint
valu
improv
interpret
discord
result
respons
pandem
commerci
molecular
assay
test
rapidli
develop
broadli
deploy
laboratori
worldwid
although
assay
report
correl
well
sought
compar
xpress
sar
modular
sar
wuhan
cov
egen
assay
nasopharyng
np
swab
low
level
rna
thirtyseven
np
swab
studi
includ
sampl
moder
cycl
threshold
ct
neg
overal
concord
initi
comparison
concord
sampl
ct
valu
rang
discord
amongst
sampl
show
ct
endpoint
valu
analysi
xpress
within
discord
sampl
note
two
endpoint
valu
detect
test
three
commerci
assay
compar
np
swab
moder
ct
valu
high
ct
valu
less
concord
importantli
analysi
endpoint
valu
improv
interpret
discrep
result
global
pandem
caus
challeng
healthcar
system
throughout
world
time
diagnosi
case
subsequ
infect
control
public
health
contain
measur
essenti
healthcar
facil
commun
one
world
health
organ
key
tenet
control
pandem
build
maintain
public
health
capac
includ
detect
symptomat
case
test
suspect
case
within
hour
specimen
collect
selfisol
confirm
case
contact
trace
confirm
case
laboratori
test
crucial
compon
process
emerg
viru
ongo
evolut
diagnost
molecular
test
includ
array
laboratori
develop
test
commerci
highvolum
autom
throughput
well
abil
process
specimen
nasopharyng
np
swab
use
kit
averag
expect
laboratori
test
time
platform
approxim
hour
rapid
molecular
assay
provid
result
minut
xpress
cepheid
sunnyval
ca
also
recent
receiv
fda
eua
comparison
show
high
overal
concord
public
health
crisi
rapid
molecular
assay
consider
impact
abil
make
immedi
decis
regard
exampl
isol
nonadher
patient
assess
infect
risk
healthcar
worker
perform
invas
procedur
critic
ill
patient
abil
molecular
assay
detect
infect
limit
thirtyseven
sampl
ten
sampl
ct
valu
twentytwo
ct
valu
five
sampl
neg
overal
concord
initi
comparison
concord
sampl
ct
valu
result
compar
shown
tabl
respect
among
sampl
ct
valu
thirteen
initi
detect
assay
nine
assay
discord
within
subgroup
five
discord
result
two
sampl
endpoint
valu
one
posit
altern
assay
note
sampl
tabl
clinic
follow
test
j
u
r
n
l
p
r
e
p
r
f
patient
posit
twentytwo
day
prior
use
assay
ct
valu
suggest
followup
test
repres
viral
clearanc
complet
concord
xpress
assay
sampl
ct
valu
compar
previous
publish
data
indic
concord
overal
agreement
lower
studi
aim
assess
challeng
diagnost
sampl
low
level
viral
rna
interestingli
review
result
discord
signal
endpoint
valu
sampl
detect
sampl
base
previou
studi
endpoint
valu
flursv
laboratori
would
test
neg
sampl
endpoint
valu
second
assay
due
concern
low
level
viral
load
includ
two
sampl
endpoint
valu
sampl
tabl
concord
assay
would
importantli
absenc
endpoint
valu
review
test
discord
rate
may
result
laboratori
reli
exclus
assay
report
neg
result
sampl
harbor
low
level
viral
rna
expans
test
identifi
presymptomat
patient
number
specimen
fall
low
level
viral
rna
rang
may
expect
increas
repeat
test
neg
result
may
indic
secondari
method
clinic
infect
prevent
control
public
health
implic
detect
sampl
low
level
viral
rna
patient
present
earli
studi
viral
dynam
suggest
may
low
burden
diseas
potenti
miss
diagnosi
patient
serv
ongo
reservoir
transmiss
within
commun
healthcar
facil
diagnos
patient
situat
testbas
strategi
prefer
discontinu
infect
control
precaut
identif
patient
low
viral
load
essenti
avoid
prematur
discontinu
although
detect
viral
rna
pcr
may
correl
live
transmiss
viru
conserv
approach
discontinu
transmissionbas
precaut
may
indic
given
strategi
primarili
use
highrisk
popul
inpati
sever
immunocompromis
patient
longterm
care
facil
resid
limit
studi
includ
small
sampl
size
due
intend
aim
low
posit
sampl
inher
test
low
posit
discord
result
tabl
could
result
sampl
bia
specimen
storag
assay
designsensit
addit
unabl
test
sampl
three
assay
use
assay
refer
ct
test
howev
prospect
comparison
nasopharyng
swab
report
overal
agreement
good
correl
ct
pragmat
reason
two
assay
alreadi
implement
laboratori
due
limit
sampl
volum
high
demand
patient
test
laboratori
need
balanc
kit
use
verif
versu
clinic
test
report
test
characterist
three
commerci
assay
specimen
low
level
viral
rna
laboratori
integr
differ
test
platform
optim
patient
care
highvolum
test
rapid
test
consid
author
relev
conflict
interest
disclos
j
u
r
n
l
p
r
e
p
r
f
